Biocartis Announces Six Idylla™ Abstracts For AMP 2024
23 Oct 2024 //
GLOBENEWSWIRE
Biocartis Appoints Gina Wallar As CBO, Judith Vacchino As VP Marketing
10 Jun 2024 //
GLOBENEWSWIRE
Biocartis Update On Annual Report Publication, Meeting
09 May 2024 //
GLOBENEWSWIRE
Biocartis & Merck to Collab on Improving Patient Access to Personalized Medicine
07 May 2024 //
PHARMIWEB
Biocartis, Merck Collaborate On Personalized Medicine In MENA
06 May 2024 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
10 Jan 2024 //
GLOBENEWSWIRE
Biocartis Holdings: Recapitalization completed and product portfolio expansion
22 Nov 2023 //
GLOBENEWSWIRE
Biocartis Hosts Corporate Workshop and Announces Seven Idylla
13 Nov 2023 //
GLOBENEWSWIRE
Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors
31 Oct 2023 //
GLOBENEWSWIRE
Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla
19 Oct 2023 //
GLOBENEWSWIRE
Biocartis Honors Breast Cancer Awareness Month with Launch of Cancer Portfolio
16 Oct 2023 //
GLOBENEWSWIRE
Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies
12 Oct 2023 //
GLOBENEWSWIRE
Press Release Biocartis Group NV: Disclosure of transparency notification
02 Oct 2023 //
GLOBENEWSWIRE
Biocartis announces H1 2023 Results
26 Sep 2023 //
GLOBENEWSWIRE
Biocartis Group: Agreement regarding recapitalization of operating subsidiaries
26 Sep 2023 //
GLOBENEWSWIRE
Biocartis 2023 half-year results webcast on 26 September 2023
20 Sep 2023 //
GLOBENEWSWIRE
Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders
28 Aug 2023 //
GLOBENEWSWIRE
Biocartis Announces 2023 Half-Year Results on 26 September 2023
24 Aug 2023 //
GLOBENEWSWIRE
Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients
10 Aug 2023 //
GLOBENEWSWIRE
Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
18 Jul 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
30 Jun 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
20 Jun 2023 //
GLOBENEWSWIRE
Biocartis announces planned operational reorganization
15 Jun 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
08 Jun 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis announces resignation CFO
05 Jun 2023 //
GLOBENEWSWIRE
Biocartis Group: Results of the Annual Shareholders Meeting held on 12 May 2023
12 May 2023 //
GLOBENEWSWIRE
Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test
09 May 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis Reports Results of 1Q of 2023
20 Apr 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO
11 Apr 2023 //
GLOBENEWSWIRE
Biocartis Announces Publication of 2022 Annual Report
11 Apr 2023 //
GLOBENEWSWIRE
Invitation to the Annual Shareholders Meeting
11 Apr 2023 //
GLOBENEWSWIRE
Biocartis & APIS Assay Sign Collaboration for Subtyping Test on Idylla platform
04 Apr 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
31 Mar 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
03 Mar 2023 //
GLOBENEWSWIRE
Biocartis announces the US FDA 510(k) clearance for the Idylla MSI Test
02 Mar 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
28 Feb 2023 //
GLOBENEWSWIRE
Biocartis Creates Share Option Plan and Cancels Outstanding Pool
24 Feb 2023 //
GLOBENEWSWIRE
Biocartis announces 2022 results and 2023 outlook
23 Feb 2023 //
GLOBENEWSWIRE
Biocartis announces change in Board composition
22 Feb 2023 //
GLOBENEWSWIRE
Biocartis Announces 2022 Full Year Results on 23 February 2023
16 Feb 2023 //
GLOBENEWSWIRE
Biocartis Announces the Launch of Assay Developed With the New Idylla Flex Tech
09 Feb 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
31 Jan 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES
17 Jan 2023 //
GLOBENEWSWIRE
Biocartis: Completion of Comprehensive Recapitalization Transactions
16 Jan 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notifications
04 Jan 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Completion of Mandatory Conversion
16 Dec 2022 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notifications
09 Dec 2022 //
GLOBENEWSWIRE
Biocartis : Mandatory Conversion Bondholder Notification
05 Dec 2022 //
GLOBENEWSWIRE
Biocartis Group NV: Disclosure of a transparency notification
02 Dec 2022 //
GLOBENEWSWIRE
Biocartis Announces 55.91% of Offered Shares
29 Nov 2022 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis Announces Successful Rights Offering
29 Nov 2022 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
29 Nov 2022 //
GLOBENEWSWIRE
Biocartis Group NV: Expected Mandatory Conversion Bondholder Notification
28 Nov 2022 //
GLOBENEWSWIRE
Biocartis launches a rights offering of a maximum of 33,476,932 offered shares
15 Nov 2022 //
GLOBENEWSWIRE
Press release Biocartis Group NV: New Idylla™ EGFR Study Shows Reduction
08 Nov 2022 //
GLOBENEWSWIRE
Biocartis Announces Nine Idylla Studies to be Published at Upcoming AMP
31 Oct 2022 //
GLOBENEWSWIRE
Biocartis Announces Conversion of Portion of Convertible Loan into New Shares
28 Oct 2022 //
GLOBENEWSWIRE
Results of the Extraordinary Shareholders’ Meeting held on 27 October 2022
27 Oct 2022 //
GLOBENEWSWIRE
Biocartis Reports Results of Third Quarter of 2022
21 Oct 2022 //
GLOBENEWSWIRE
Biocartis Announces First Drawdown of New Convertible Term Loans
19 Oct 2022 //
GLOBENEWSWIRE